Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Questex Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Questex Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Alnylam Pharmaceuticals
Biotech
Rubius execs depart as the walls close in—Chutes & Ladders
Rubius execs leave as the walls close in. Ambrx lands a new CEO. Alexion co-founder joins new J.P. Morgan investment venture.
Max Bayer
,
Gabrielle Masson
Nov 4, 2022 9:30am
New Beam-buoyed biotech takes flight, gravitating toward RNA
Sep 7, 2022 11:22am
Alnylam sees therapy potential in gene for reducing body fat
Aug 1, 2022 12:39pm
Alnylam stays on Calliditas' heels, passing a phase 2 checkpoint
Jun 9, 2022 10:21am
Carlyle's Abingworth buy brings $2 billion for life sciences
Apr 12, 2022 10:00am
The top 10 M&A targets in biotech for 2022
Feb 15, 2022 8:00am
